European Journal of Biomedical and Pharmaceutical Sciences

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ANTI-DIABETIC AGENT DAPAGLIFLOZIN IN BULK FORM AND MARKETED PHARMACEUTICAL DOSAGE FORM

A. Vaishnavi*, M. Venkatesh and A. Yasodha

ABSTRACT

A novel, simple, accurate, precise, sensitive and specific analytical RP-HPLC method was developed and validated for the quantitative estimation of Dapagliflozin in bulk drugs and pharmaceutical dosage form. Chromatographic separation was achieved on an Symmetry ODS C18 (4.6×250mm, 5µm) analytical column using mobile phase composition of methanol and Phosphate Buffer in ratio of (35: 65 v/v) that was set at a flow rate of 1.0μl/min with detection of 235 nm. The retention time of Dapagliflozin was found to be 3.006min. The drug was analyzed by following the guidelines of International conference on Harmonization (ICH). This drug showing linearity in the concentration range of 6-14µg/ml and the correlation coefficient showing R2 = 0.9996. The % Recoveries showing within the limits. The presentation of the method was validated according to the present ICH guidelines for accuracy, precision and robustness, Linearity, limit of quantification, limit of detection linearity.

Keywords: Dapagliflozin, RP-HPLC, Method Development, Accuracy, Precision.